Armistice Capital LLC Cuts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Armistice Capital LLC lessened its stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 17.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 300,000 shares of the company’s stock after selling 64,000 shares during the period. Armistice Capital LLC owned about 1.11% of Vistagen Therapeutics worth $1,044,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. AdvisorShares Investments LLC purchased a new stake in shares of Vistagen Therapeutics during the 4th quarter worth approximately $279,000. ADAR1 Capital Management LLC bought a new position in Vistagen Therapeutics during the fourth quarter valued at $1,262,000. BVF Inc. IL purchased a new stake in Vistagen Therapeutics in the fourth quarter worth $10,280,000. Acadian Asset Management LLC bought a new stake in shares of Vistagen Therapeutics in the first quarter valued at $169,000. Finally, Great Point Partners LLC purchased a new position in shares of Vistagen Therapeutics during the 4th quarter valued at $9,554,000. Institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Trading Down 2.0 %

Shares of VTGN stock opened at $3.00 on Friday. The firm’s 50 day moving average is $3.37 and its 200 day moving average is $3.92. The stock has a market capitalization of $81.08 million, a P/E ratio of -1.45 and a beta of 0.80. Vistagen Therapeutics, Inc. has a 12 month low of $2.45 and a 12 month high of $5.86.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.30 million. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. During the same quarter in the prior year, the business posted ($0.94) earnings per share. On average, equities analysts predict that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.